Merck & Co Inc (MRK)

MRK on New York Consolidated

58.15USD
25 Jul 2014
Price Change (% chg)

$-0.06 (-0.10%)
Prev Close
$58.21
Open
$58.13
Day's High
$58.36
Day's Low
$57.92
Volume
5,533,511
Avg. Vol
--
52-wk High
--
52-wk Low
--

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.40
Market Cap (Mil.): $169,936.20
Shares Outstanding (Mil.): 2,922.38
Dividend: 0.44
Yield (%): 3.03

Financials

  MRK Industry Sector
P/E (TTM): 38.05 35.64 36.09
EPS (TTM): 1.53 -- --
ROI: 5.51 18.92 18.19
ROE: 8.77 19.68 19.06
Search Stocks

Pfizer's need for deal looms larger with earnings report

NEW YORK - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

1:36am EDT

Merck aims to hike revenues in China to 1 bln eur by 2018

FRANKFURT, July 26 - Merck will start offering non-prescription drugs in China as part of a push to double revenues in the region to 1 billion euros ($1.3 billion) by 2018, Chief Executive Karl-Ludwig Kley told German weekly Wirtschaftswoche.

26 Jul 2014

What to Watch in the Week Ahead and on Monday, July 28

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Markets await next week looking for answers to a couple of specific questions: how much did the economy rebound in the second quarter, how strong is the jobs market, and is the Fed going to alter its position at all? With stock markets at a high and

25 Jul 2014

U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug

- Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.

11 Jul 2014

UPDATE 1-U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug

July 11 - Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.

11 Jul 2014

UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands

* Coppertone, Dr. Scholl's draw interest after $14 bln deal

01 Jul 2014

CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands

(Corrects fourth paragraph to read "portfolio acquired from Merck", not "portfolio acquired by Merck")

01 Jul 2014

Merck nausea drug works in children in late-stage trial

- Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.

30 Jun 2014

UPDATE 1-Merck nausea drug works in children in late-stage trial

June 30 - Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.

30 Jun 2014

Merck nausea drug works in children in late-stage trial

June 30 - Merck & Co Inc said its drug for treating chemotherapy-induced nausea and vomiting, Emend, was shown to be more effective than a placebo in a late-stage trial in children.

30 Jun 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks